🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11447563

    Tumor selective macropinocytosis-dependent rapidly internalizing antibodies

    The Regents of the University of California · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11447830

    Gene signatures to predict drug response in cancer

    The Board of Regents of the University of Texas System · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11446332

    Combinatorial cancer immunotherapy

    Senti Biosciences, Inc. · Granted Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11439709

    Phospholipid ether analogs as cancer-targeting drug vehicles

    CELLECTAR BIOSCIENCES, INC. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11440939

    Anticancer peptides

    IDP DISCOVERY PHARMA, S.L. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11439632

    Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients

    Northwestern University · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11439635

    B cell lymphoma 6 protein (BCL6) as a target for treating diabetes mellitus and non-alcoholic fatty liver disease

    Northwestern University · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11439683

    Anti-angiogenic therapy of metastatic colorectal cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11439669

    C. novyi for the treatment of solid tumors in humans

    Biomed Valley Discoveries, Inc. · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11434300

    Methods and antibody compositions for tumor treatment

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11433137

    Compounds for treating cancer

    BicycleRD Limited · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11433143

    Nano-enabled immunotherapy in cancer

    The Regents of the University of California · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11432547

    Inhibitors of GRB2-associated binding protein 1 (GAB1) and methods of treating cancer using the same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11433097

    Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

    Iovance Biotherapeutics, Inc. · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11426409

    Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers

    The Regents of the University of Colorado · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11426385

    Methods of improving cancer chemotherapy

    THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11427816

    Cancer treatment through RLIP76 partial depletion

    The Board of Regents of the University of Texas System · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11427646

    Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis

    B CELL DESIGN · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11419898

    Combinatorial cancer immunotherapy

    Senti Biosciences, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11421284

    Methods for predicting drug responsiveness in cancer patients

    Allarity Therapeutics Europe ApS · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11419934

    Use of VDAS to enhance immunomodulating therapies against tumors

    Oncotelic Therapeutics, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11419844

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11421010

    T cells expressing membrane-anchored IL-12 for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11421034

    Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

    Five Prime Therapeutics, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11413329

    Cancer cell trap

    The Board of Regents of the University of Texas System · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11414488

    Methods for treating cancer

    BicycleRD Limited · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11414458

    Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies

    The Board of Regents of the University of Oklahoma · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11406697

    Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus

    Regents of the University of Minnesota · Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11406643

    Targeting kinases for the treatment of cancer metastasis

    The Board of Regents of the University of Texas System · Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11401507

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11401503

    Methods of growing tumor infiltrating lymphocytes in gas-permeable containers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11401506

    Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

    Board nf Regents The Inivercitvof Texas Cvctom · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11400116

    Systems and methods for targeting cancer cells

    The Regents of the University of California · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11401341

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11396647

    Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11389497

    Pharmaceutical composition for treating cancer

    Prime Bio, Inc. · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11389432

    Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent

    Corcept Therapeutics Incorporated · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11389544

    Formation of functionalized cancer targeting nanoparticles by supramolecular co-assembly

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11389480

    Human monoclonal antibody targeting TNFR2 for cancer immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11384337

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11376313

    Cancer treatment

    Propanc Pty Ltd · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11377451

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11377491

    Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11376247

    Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11369697

    Liposome nanoparticles for tumor magnetic resonance imaging

    United Kingdom Research and Innovation · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11369637

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11365250

    Compositions and methods for cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11364235

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.